[en] Algorithms ; Antimetabolites, Antineoplastic/therapeutic use ; Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Cytarabine/therapeutic use ; Enzyme Inhibitors/therapeutic use ; Fusion Proteins, bcr-abl/antagonists & inhibitors ; Hematopoietic Stem Cell Transplantation ; Humans ; Interferon-alpha/therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy ; Piperazines/therapeutic use ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Pyrimidines/therapeutic use
[en] This review article describes the identification of the tyrosine kinase BCR/ABL as the hallmark of chronic myeloid leukemias (CML) as well as the development of a specific inhibitor of this tyrosine kinase, the STI571 (Glivec, imatinib mesylate). The authors discuss the results of a phase I and three phase II trials reporting the efficacy of STI571 as treatment for CML patients and propose two simplified algorithms that may help to guide decision-making for the individual patient.
[Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
